Stem Cell Therapeutics Corp.

Stem Cell Therapeutics Corp.

June 22, 2009 10:39 ET

Stem Cell Therapeutics Corp. Announces Presentations at Public Forum Discussing Stem Cell Therapies in Alberta

Regenerative Medicine: Stem Cell Therapeutics, the Future of Health Care

CALGARY, ALBERTA--(Marketwire - June 22, 2009) - Stem Cell Therapeutics Corp. ("SCT") (TSX VENTURE:SSS) announced today that Dr. Samuel Weiss, Director of the Hotchkiss Brain Institute at the University of Calgary, will be providing the keynote address and Dr. Allen Davidoff, VP Product Development at SCT, will be a member of a response panel at the Alberta Council of Technologies ("ABCtech") hosted event in Calgary, June 23, 2009, at the Alberta Research Council. Dr Weiss' work founded SCT, and he remains a key member of SCT's Scientific Advisory Board.

ABCtech is co-hosting back-to-back events in Edmonton and Calgary on June 22nd and 23rd. In Edmonton, Dr. Martin Ferguson-Pell, Dean of the Faculty of Rehabilitation Medicine of the University of Alberta, while in Calgary, Dr. Samuel Weiss will demystify stem cell therapies and outline the vast opportunities they represent to groups of diverse audiences including policymakers, healthcare professionals, business entrepreneurs and the interested general public.

The response panel consists of ethicists, investors, researchers and public policy and rehabilitation specialists, who will discuss the dramatic implications of stem cell therapies for treatment of degenerative diseases associated with ageing, injury and lifestyle.

Both events are being co-hosted by the Alberta Council of Technologies and the Alberta Health Industry Association and are being sponsored by Pfizer Inc. and the Edmonton and Calgary Associations for Advanced Technology.

About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a Canadian public biotechnology company (TSX VENTURE:SSS) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient's own resident stem cells. The Company's programs aim to repair brain and nerve function lost due to disease or injury. The Company's extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases such as traumatic brain injury, multiple sclerosis, Huntington's disease, Alzheimer's disease, and ALS.

These securities have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons unless an applicable exemption from U.S. registration requirements is available.

Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information